Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$14.31 USD

14.31
3,247,778

+0.01 (0.07%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $14.32 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cooper Companies Q2 Earnings Likely to Reflect Seasonal Trends

by Zacks Equity Research

COO's fiscal second-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.

Zacks Equity Research

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Dentsply Sirona (XRAY) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why Dentsply International (XRAY) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Dentsply (XRAY) Reliance on International Sales: What Investors Need to Know

by Zacks Equity Research

Evaluate Dentsply's (XRAY) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks Equity Research

XRAY Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

DENTSPLY SIRONA's customer-centric innovation and operational efficiency drive its first-quarter 2025 performance despite global macroeconomic challenges.

Zacks Equity Research

Dentsply (XRAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Dentsply (XRAY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Dentsply International (XRAY) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 48.28% and 3.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stay Ahead of the Game With Dentsply (XRAY) Q1 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Dentsply (XRAY) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?

by Zacks Equity Research

XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.

Zacks Equity Research

Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates

by Zacks Equity Research

ProDex (PDEX) delivered earnings and revenue surprises of 108.51% and 1.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Dentsply International (XRAY) Q1 Earnings Expected to Decline

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Align Technology (ALGN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 7.58% and 0.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?

by Zacks Equity Research

ProDex (PDEX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now

by Zacks Equity Research

XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.

Indrajit Bandyopadhyay headshot

4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind

by Indrajit Bandyopadhyay

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.

Zacks Equity Research

Solventum Partners With SprintRay for Same-Day Dental Restorations

by Zacks Equity Research

SOLV partners with SprintRay to introduce an innovative solution for same-day dental restorations, enhancing efficiency, precision and patient care in digital dentistry.

Zacks Equity Research

Investing in Dentsply (XRAY)? Don't Miss Assessing Its International Revenue Trends

by Zacks Equity Research

Explore Dentsply's (XRAY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks Equity Research

XRAY Q4 Earnings & Revenues Miss Estimates, Gross Margin Down

by Zacks Equity Research

DENTSPLY SIRONA's fourth-quarter results showcase dismal segmental performance with declining adjusted operating income.

Zacks Equity Research

Dentsply International (XRAY) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of -39.53% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dentsply (XRAY) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Evaluate the expected performance of Dentsply (XRAY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Henry Schein (HSIC) Meets Q4 Earnings Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DENTSPLY SIRONA to Post Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

XRAY is likely to have faced a tough fourth quarter with Byte's revenue loss, weak U.S. equipment demand and implant pressures.

Zacks Equity Research

Earnings Preview: Dentsply International (XRAY) Q4 Earnings Expected to Decline

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.